Clinical Trial

Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Protocol Amendment History 1 change
minor Trial arms changed: 4 -> 3 2026-08-01
Trial Details
NCT Number NCT07602127
Lead Sponsor Zhongmou Therapeutics
Conditions Geographic Atrophy
Enrollment 24 participants
Start Date 2026-07-01
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31